Non-Insulin Antidiabetics Market Soars to $8 Billion by 2020, to be Driven by Explosion of Generics As Actos Exclusivity Expires
FARMINGTON, June 12, 2012 /PRNewswire-iReach/ -- Non-insulin dependent (Type 2) diabetes accounts for 90% of all diagnosed cases of diabetes. The leading non-insulin antidiabetic Actos will lose its patent exclusivity in August 2012, offering significant market opportunities for competing generics. Having accurate market data and analysis will be essential to companies seeking to compete in this space. With premium market research from the world's leading publishers, Global Information Inc. will help businesses stay on the cutting edge with the best forecasts, research, and analyses.
As such, Global Information is pleased to announce the immediate availability of two significant new Non-Insulin Antidiabetics market research reports.
Market and Product Forecasts: Non-Insulin Antidiabetics
With the loss of exclusivity for the leading non-insulin antidiabetic Actos franchise in August 2012, new generic Antidiabetic competitor launches include the first once-weekly GLP-1 agonists and the oral SGLT-2 inhibitor class, to compete in an increasingly crowded treatment algorithm in type 2 diabetes.
This new report Non-Insulin Antidiabetics market research report offers forecasts for non-insulin antidiabetic brands, 2011 through 2020, with the aim of helping businesses quantify the sales potential late-stage pipeline products and assess the impact of generic competition and sales restrictions on the Actos (pioglitazone) franchise.
Despite moderate efficacy, a benign safety profile and oral delivery will mean that DPP-IV inhibitors continue to dominate branded non-insulin antidiabetics, with the class forecast to be worth over $8 billion in 2020, led by the gold-standard Januvia. The GLP-1 agonist class sees once-weekly product launch, but doubts about their efficacy will allow once-daily Victoza (liraglutide; Novo Nordisk) to retain a leading position in the class and reach blockbuster status early in the forecast period.
An Executive Summary of this analysis and a free sample of the full report are available at http://www.giiresearch.com/report/dc243919-market-product-forecasts-non-insulin-antidiabetics.html
Non-Insulin Diabetes Management: Products, Players, Markets and Forecasts
Incidence of non-insulin dependent (Type 2) diabetes has witnessed double-digit growth. Type 2 diabetes accounts for about 90% of all diagnosed cases of diabetes. Pipeline activity is high.
New market research, Non-Insulin Diabetes Management: Products, Players, Markets and Forecasts, projects the market revenues of drugs for managing Type 2 diabetes to grow by 14% between 2011 and 2016, further fuelled by the convergence of environmental factors, lifestyle factors and increased patient longevity.
The report analyzes and evaluates non-insulin or insulin analog drug products and development-stage candidates for glycemic control, including Commercial Product Assessments for branded drugs, non-FDA approved drugs, and Generics. The report features an overview of economic, technology, and regulatory factors influencing the diabetes management markets.
An Executive Summary of this analysis and a free sample of the full report are available at http://www.giiresearch.com/report/grey241565-non-insulin-diabetes-management-products-players.html
About Global Information Inc. Global Information (GII) (http://www.giiresearch.com) is an information service company partnering with over 300 research companies around the world. Global Information has been in the business of distributing technical and market research for more than 25 years. Expanded from its original headquarters in Japan, Global Information now has offices in Korea, Taiwan, Singapore, Europe and the United States.
SOURCE Global Information, Inc.Back to top